Last edition
News about Market
Nektar Therapeutics and UCSF collaborate to study TNFR2 agonist NKTR-0165 in multiple sclerosis, aiming to explore its potential for neuroprotection and reduced neurodegeneration.
Market | 18/02/2026 | By News Bureau
Simplified once-monthly schedule for RYBREVANT FASPRO matches bi-weekly efficacy, reduces clinic visits and maintains a strong safety profile.
Market | 18/02/2026 | By News Bureau
Newron Pharmaceuticals Secures Euro 38 Million to Advance Phase III Schizophrenia Programme
Newron Pharmaceuticals strengthens its funding base with a multi-tranche equity raise to support late-stage development of evenamide in treatment-resistant schizophrenia.
Market | 17/02/2026 | By News Bureau
Hikal Ltd posts quarterly loss as pharma manufacturing operations return to recovery
Hikal Ltd reported a net loss of INR 5.9 crore in the third quarter of FY26, compared with a profit of INR 17.2 crore in the corresponding quarter last year. Despite the loss, total revenue from operations increased 10.4 per cent year on year to INR 494.3 crore, up from INR 447.7 crore.
Market | 16/02/2026 | By Darshana
STADA and Bio-Thera Secure EU Marketing Approval for Golimumab Biosimilar Gotenfia
European Commission authorises Gotenfia, referencing Simponi, for multiple autoimmune diseases across EU and EEA markets.
Market | 16/02/2026 | By News Bureau
Lupin Posts 37 percent Q3 Profit Growth on Record US Sales
Lupin Limited reported a 37.4 percent year-on-year increase in net profit for the third quarter ended December 31, 2025, reaching INR 1,180.5 crore, compared with INR 858.9 crore in the same quarter last year.
Market | 13/02/2026 | By Darshana
Pharma-to-Wellness Play: USV Secures Controlling Interest in Wellbeing Nutrition
USV has acquired a 79 percent stake in Wellbeing Nutrition, a leading consumer healthcare and nutrition company, in a deal valued at INR 1,583 crore. The acquisition marks a strategic move by USV to strengthen its presence in the fast-growing consumer wellness and nutrition segment.
Market | 12/02/2026 | By Darshana
Iqvia and DCRI have formed a strategic collaboration to enhance the design and execution of obesity and cardiometabolic clinical trials, combining global operational capabilities with academic research expertise.
Market | 12/02/2026 | By News Bureau
IOL Chemicals and Pharmaceuticals Reports Q3 and 9M FY26 Results
IOL Chemicals and Pharmaceuticals reported strong Q3 and nine-month FY26 results, with profit before exceptional items rising 39 percent year-on-year, supported by margin expansion and improved operational performance.
Market | 12/02/2026 | By News Bureau
Sobi has acquired Arthrosi Therapeutics, adding phase III gout candidate pozdeutinurad (AR882) to its portfolio, with trial results expected in 2026.
Market | 11/02/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy